RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Protagonist Therapeutics Stock

Protagonist Therapeutics Liabilities 2025

Protagonist Therapeutics Liabilities

21.27 M USD

Ticker

PTGX

ISIN

US74366E1029

WKN

A2AP32

In 2025, Protagonist Therapeutics's total liabilities amounted to 21.27 M USD, a -34.14% difference from the 32.3 M USD total liabilities in the previous year.

Protagonist Therapeutics Aktienanalyse

What does Protagonist Therapeutics do?

Protagonist Therapeutics Inc is a biopharmaceutical company focused on the development and commercialization of novel peptide therapies. The company was founded in 2002 and is headquartered in Newark, California. The history of Protagonist Therapy began with the discovery of a new type of molecules called peptides, which can be used as potential drugs for various diseases. This discovery was the result of years of research and collaboration between academics and leading pharmaceutical companies. Protagonist Therapeutics' business model is focused on developing and distributing new peptide therapies in the pharmaceutical industry. The company works closely with leading academics and biotechnology companies to advance its research and development projects. Protagonist Therapeutics is divided into several divisions focusing on different therapeutic areas. These include gastrointestinal diseases, immunology, and oncology. Each division works on developing new peptide therapies specifically tailored to their respective therapeutic areas. One example of a product from Protagonist Therapeutics is PTG-300, which was developed for the treatment of iron deficiency anemia. PTG-300 is a synthetic peptide that promotes increased iron uptake in the body to combat iron deficiency. Another product from Protagonist Therapeutics is PTG-200, which was developed for the treatment of inflammatory bowel diseases such as ulcerative colitis and Crohn's disease. PTG-200 is a peptide that blocks the action of certain enzymes that amplify inflammation in the intestine. Overall, Protagonist Therapeutics aims to establish itself as a leading provider of peptide therapies in the pharmaceutical industry. The company has a strong financial foundation, including a successful IPO in 2016, and is continuously working on developing new products to expand and grow the company. Protagonist Therapeutics ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Liabilities Details

Assessing Protagonist Therapeutics's Liabilities

Protagonist Therapeutics's liabilities constitute the company's financial obligations and debts owed to external parties and stakeholders. They are categorized into current liabilities, due within a year, and long-term liabilities, which are due over a longer period. A detailed assessment of these liabilities is crucial for evaluating Protagonist Therapeutics's financial stability, operational efficiency, and long-term viability.

Year-to-Year Comparison

By comparing Protagonist Therapeutics's liabilities year-over-year, investors can identify trends, shifts, and anomalies in the company’s financial positioning. A decrease in total liabilities often signals financial strengthening, while an increase might indicate enhanced investments, acquisitions, or potential financial strain.

Impact on Investments

Protagonist Therapeutics's total liabilities play a significant role in determining the company's leverage and risk profile. Investors and analysts examine this aspect meticulously to ascertain the firm’s ability to meet its financial obligations, which influences investment attractiveness and credit ratings.

Interpreting Liability Fluctuations

Shifts in Protagonist Therapeutics’s liability structure indicate changes in its financial management and strategy. A reduction in liabilities reflects efficient financial management or debt payoffs, while an increase may suggest expansion, acquisition activities, or accruing operational expenses, each carrying distinct implications for investors.

Frequently Asked Questions about Protagonist Therapeutics stock

What is the level of liabilities of Protagonist Therapeutics this year?

Protagonist Therapeutics has a debt balance of 21.27 M USD this year.

What were the liabilities of Protagonist Therapeutics compared to the previous year?

The liabilities of Protagonist Therapeutics have increased by -34.14% dropped compared to the previous year.

What are the consequences of high debt for investors of Protagonist Therapeutics?

High liabilities can pose a risk for investors of Protagonist Therapeutics, as they can weaken the company's financial position and impair its ability to meet its obligations.

What consequences do low liabilities have for investors in Protagonist Therapeutics?

Low liabilities mean that Protagonist Therapeutics has a strong financial position and is able to meet its obligations without overburdening its finances.

How does an increase in liabilities of Protagonist Therapeutics affect the company?

An increase in liabilities of Protagonist Therapeutics can lead to the company having more obligations and potentially find it more difficult to meet its financial commitments.

How does a reduction in the liabilities of Protagonist Therapeutics affect the company?

A decrease in the liabilities of Protagonist Therapeutics can lead to the company having fewer obligations and a stronger financial position, which can make it easier for the company to fulfill its financial commitments.

What are some factors that influence the liabilities of Protagonist Therapeutics?

Some factors that can influence the liabilities of Protagonist Therapeutics include investments, acquisitions, operating costs, and sales development.

Why is the level of liabilities of Protagonist Therapeutics so important for investors?

The liabilities of Protagonist Therapeutics are important for investors as they serve as an indicator of the company's financial stability and provide investors with information on how the company meets its financial obligations.

What strategic measures can Protagonist Therapeutics take to modify the liabilities?

To change its liabilities, Protagonist Therapeutics can take measures such as cost savings, increasing revenue, selling assets, raising investments, or forming partnerships. It is important for the company to conduct a thorough review of its financial situation to choose the best strategic actions.

How much dividend does Protagonist Therapeutics pay?

Over the past 12 months, Protagonist Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Protagonist Therapeutics is expected to pay a dividend of 0 USD.

What is the dividend yield of Protagonist Therapeutics?

The current dividend yield of Protagonist Therapeutics is .

When does Protagonist Therapeutics pay dividends?

Protagonist Therapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Protagonist Therapeutics?

Protagonist Therapeutics paid dividends every year for the past 0 years.

What is the dividend of Protagonist Therapeutics?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Protagonist Therapeutics located?

Protagonist Therapeutics is assigned to the 'Health' sector.

Wann musste ich die Aktien von Protagonist Therapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Protagonist Therapeutics from 1/17/2025 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 1/17/2025.

When did Protagonist Therapeutics pay the last dividend?

The last dividend was paid out on 1/17/2025.

What was the dividend of Protagonist Therapeutics in the year 2024?

In the year 2024, Protagonist Therapeutics distributed 0 USD as dividends.

In which currency does Protagonist Therapeutics pay out the dividend?

The dividends of Protagonist Therapeutics are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Protagonist Therapeutics

Our stock analysis for Protagonist Therapeutics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Protagonist Therapeutics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.